Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein Sells 370 Shares

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 370 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $53.31, for a total value of $19,724.70. Following the completion of the sale, the director now directly owns 27,524 shares of the company’s stock, valued at $1,467,304.44. The trade was a 1.33 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $68.96 on Friday. The business has a fifty day moving average price of $44.36 and a 200-day moving average price of $48.84. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $79.49.

Institutional Trading of Tempus AI

A number of institutional investors and hedge funds have recently bought and sold shares of TEM. First Horizon Advisors Inc. bought a new position in shares of Tempus AI in the third quarter worth approximately $30,000. FNY Investment Advisers LLC purchased a new position in Tempus AI in the 4th quarter worth approximately $67,000. IFP Advisors Inc bought a new position in Tempus AI in the 4th quarter valued at approximately $76,000. US Bancorp DE purchased a new stake in Tempus AI during the 4th quarter valued at $80,000. Finally, Vestor Capital LLC bought a new stake in shares of Tempus AI in the 3rd quarter worth $153,000. 24.22% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on TEM. Loop Capital cut their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and lifted their price objective for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Guggenheim initiated coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price for the company. Piper Sandler restated a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $58.55.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.